FDA — authorised 28 September 2018
- Application: NDA207356
- Marketing authorisation holder: INSMED INC
- Status: supplemented
FDA authorised Arikayce on 28 September 2018
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. FDA authorised it on 28 September 2018; FDA has authorised it.
INSMED INC holds the US marketing authorisation.